NASDAQ | VICL: 1.02  +0.01
Clinical Trials

Ongoing Clinical Trials

Phase 2 Clinical Trial: VL-2397 Antifungal for the Treatment of Invasive Aspergillosis
A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients. For more information, please go to the NCT03327727 trial listing at


P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.